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Combined Lung Ultrasound (LUS) and Focused UltraSound for Intensive Care heart (FUSIC 
heart - formerly Focused Intensive Care Echocardiography, FICE) can aid diagnosis, risk 
stratification and management in COVID-19. However, data on its application and results 
are limited to small studies in varying countries and hospitals. This United Kingdom (UK) 
national service evaluation study assessed how combined LUS and FUSIC Heart were used in 
COVID-19 Intensive Care Unit (ICU) patients during the first wave of the pandemic. 
Method: 
12 trusts across the UK registered for this prospective study. LUS and FUSIC Heart data were 
obtained, using a standardised data set including scoring of abnormalities, between 1st of 
February 2020 to the 30th July 2020. The scans were performed by intensivists with FUSIC 
Lung and Heart competency as a minimum standard. Data was anonymised locally prior to 
transfer to a central database. 
Results: 
372 studies were performed on 265 patients. There was a small but significant relationship 
between LUS score >8 and 30-day mortality (OR 1.8). Progression of score was associated 
with an increase in 30-day mortality (OR 1.2). 30-day mortality was increased in patients 
with right ventricular (RV) dysfunction (49.4% vs 29.2%). Severity of LUS score correlated 
with RV dysfunction (p < 0.05).  Change in management occurred in 65% of patients 
following a combined scan. 
Conclusions: 
In COVID-19 patients there is an association between lung ultrasound score severity, RV 
dysfunction and mortality identifiable by combined LUS and FUSIC Heart.      The use of 12-
point LUS scanning resulted in similar risk score to 6-point imaging in the majority of cases. 
Our findings suggest that serial combined LUS and FUSIC Heart on COVID-19 ICU patients 







Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a novel 
coronavirus: SARS-CoV-2. It is a heterogeneous disease with a wide spectrum of severity and 
organ dysfunction. In the UK, during the first wave of the pandemic, approximately 20% of 
hospitalised patients required admission to High Dependency Units (HDU) or ICUs1. 
 
Point of Care UltraSound (PoCUS) typically combines lung and cardiac imaging to obtain 
goal-oriented information and answer specific clinical questions. It is a non-invasive, non-
radioactive, bedside modality of imaging2. In patients with COVID-19, PoCUS can aid 
diagnosis, risk-stratification and management decisions3. However, uncertainty remains 
about how to utilise PoCUS optimally. 
 
LUS uses pleural surface changes and structural patterns of the lung to identify disease. LUS 
has a sensitivity between 90 – 100% for diagnosing infection, effusion, pneumothorax, or 
embolic phenomena4,5. Algorithms such as the BLUE protocol6 provide accessible methods 
for interpreting findings and differentiating causes of respiratory failure. 
 
Critical care echocardiography (CCE) can be a focused or advanced structural assessment, 
with the option of dynamic cardiac output monitoring. CCE has become a well-established 
adjunct to care for initial and serial assessments of the shocked patient7. Whilst CCE is 
                                               
1 Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: 
prospective observational cohort study. AB Docherty et al. BMJ 2020;369:m1985 
2 Laursen CB, Sloth E, Lassen AT, Christensen Rd, Lambrechtsen J, Madsen PH, Henriksen DP, Davidsen JR, Rasmussen F. 
Point-of-care ultrasonography in patients admitted with respiratory symptoms: a single-blind, randomised controlled trial. 
Lancet Respir Med. 2014 Aug;2(8):638-46. doi: 10.1016/S2213-2600(14)70135-3. Epub 2014 Jul 3. PMID: 24998674. 
3Hussain A. et al. Multi-organ point-of-care ultrasound for COVID-19 (PoCUS4COVID): international expert consensus. Crit 
Care. 2020 Dec 24;24(1):702. doi: 10.1186/s13054-020-03369-5. PMID: 33357240 
4 Lichtenstein D, Goldstein I, Mourgeon E, Cluzel P, Grenier P, Rouby JJ. Comparative diagnostic performances of 
auscultation, chest radiography, and lung ultrasonography in acute respiratory distress syndrome. Anesthesiology. 
2004;100(1):9–15 
5 Laursen CB, Sloth E, Lambrechtsen J, Lassen AT, Madsen PH, Henriksen DP, Davidsen JR, Rasmussen F. Focused 
sonography of the heart, lungs, and deep veins identifies missed life-threatening conditions in admitted patients with 
acute respiratory symptoms. Chest. 2013 Dec;144(6):1868-1875. doi: 10.1378/chest.13-0882. PMID: 23948720. 
6 Lichtenstein, D.A. ‘Lung ultrasound in the critically ill.’ Ann. Intensive Care 4, 1 (2014). https://doi.org/10.1186/2110-
5820-4-1 
7 Vieillard-Baron A, Millington SJ, Sanfilippo F, Chew M, Diaz-Gomez J, McLean A, Pinsky MR, Pulido J, Mayo P, Fletcher N. A 
decade of progress in critical care echocardiography: a narrative review. Intensive Care Med. 2019 Jun;45(6):770-788. doi: 




operator-dependent, focused echocardiography can provide very good correlation with 
departmental echocardiography - achieving a sensitivity of 0.91 and specificity of 0.88 for 
determining any degree of left ventricular (LV) systolic impairment8.  
 
In patients with acute respiratory distress syndrome (ARDS), CCE features of acute cor 
pulmonale (ACP) are found in 20-25%9,10. These include RV dilation, RV impairment, septal 
dyskinesia and pulmonary hypertension. Lung inflammation and      hypoxic vasoconstriction 
contribute to the disease pathology and      high positive end-expiratory pressure (PEEP) 
strategies      can be used in the management of ARDS. Once established, ACP is an 
independent risk factor for 28-day mortality in those with moderate to severe ARDS (     60%      
vs 36%     , ACP vs no ACP)     11.  
 
As COVID-19 spread towards the UK, observational data from China12 and Italy13 supported 
LUS similarities between ARDS and COVID-19 pneumonitis (thickened pleura, multiple or 
confluent B-Lines and consolidations) in spite of two clearly different phenotypes (compliant 
and non-compliant14). Scoring mechanisms were proposed that could help enable COVID-19 
                                               
8 Johnson BK, Tierney DM, Rosborough TK, Harris KM, Newell MC. Internal medicine point-of-care ultrasound assessment 
of left ventricular function correlates with formal echocardiography. J Clin Ultrasound. 2016 Feb;44(2):92-9. doi: 
10.1002/jcu.22272. Epub 2015 Jul 14. PMID: 26179460. 
9 Boissier, F., Katsahian, S., Razazi, K. et al. ‘Prevalence and prognosis of cor pulmonale during protective ventilation for 
acute respiratory distress syndrome’. Intensive Care Med 39, 1725–1733 (2013). https://doi.org/10.1007/s00134-013-
2941-9 
10 Repessé X., Charron C., Vieillard-Baron A. (2012) Right ventricular failure in ALI and ARDS. Minerva Anestesiol 78: 941–
948. 
11 Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS: ‘Acute respiratory 
distress syndrome: the Berlin Definition. ARDS Definition Task Force’, JAMA. 2012 Jun 20; 307(23):2526-33. 
12 Peng QY, Wang XT, Zhang LN; Chinese Critical Care Ultrasound Study Group (CCUSG). ‘Findings of lung ultrasonography 
of novel corona virus pneumonia during the 2019-2020 epidemic’. Intensive Care Med. 2020 May;46(5):849-850. doi: 
10.1007/s00134-020-05996-6. Epub 2020 Mar 12. PMID: 32166346; PMCID: PMC7080149. 
13 Buonsenso D, Piano A, Raffaelli F, et al. Point-of-Care Lung Ultrasound findings in novel coronavirus disease-19 
pnemoniae: a case report and potential applications during COVID-19 outbreak. Eur Rev Med Pharmacol Sci. 2020; 24(5): 
2776–80.  
14Luciano Gattinoni, Davide Chiumello, Pietro Caironi, Mattia Busana, Federica Romitti, Luca Brazzi, Luigi Camporota 
 COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020; 46(6): 1099–




diagnosis and scale illness severity15, potentially reducing the burden of pandemic on 
hospital resources.16 
 
Few studies have reported focused CCE alongside LUS in COVID-1917, but echocardiographic 
findings correlate with changes seen in ARDS, as well as case reports of acute pulmonary 
embolism, dilated cardiomyopathy and acute myocardial injury18. Across 74 patients with 
COVID-19, one study showed RV dilatation in 41% and RV dysfunction in 27%, whilst LV 
function was normal in 89%19. 
 
This paper is a nationwide service evaluation looking at the application and results of LUS 
and FUSIC Heart in combination during the first wave of COVID-19. This is a novel approach 
to the assessment of an ad hoc service managing a large number of patients with similar 
physiological needs. Data from ICUs within 12 registered trusts was analysed looking for 
observable trends that can help establish better national PoCUS practice and guidelines20. 
 
This paper describes findings from the intensive care arm of the CORONA study, a study 
jointly led by the Intensive Care Society and the Society of Acute Medicine.  
                                               
15 Volpicelli, G., Lamorte, A., & Villén, T. (2020). What's new in lung ultrasound during the COVID-19 pandemic. Intensive 
care medicine, 46(7), 1445–1448. https://doi.org/10.1007/s00134-020-06048-9 
16 Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different 
respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-1102. doi: 10.1007/s00134-
020-06033-2. Epub 2020 Apr 14. PMID: 32291463; PMCID: PMC7154064. 
17 Lazzeri C, Bonizzoli M, Batacchi S, Socci F, Matucci-Cerinic M, Peris A. Combined lung and cardiac ultrasound in COVID-
related acute respiratory distress syndrome [published online ahead of print, 2021 Mar 11]. Intern Emerg Med. 2021;1-7. 
doi:10.1007/s11739-021-02646-7 
18 Zhang L, Wang B, Zhou J, Kirkpatrick J, Xie M, Johri AM. Bedside Focused Cardiac Ultrasound in COVID-19 from the 
Wuhan Epicenter: The Role of Cardiac Point-of-Care Ultrasound, Limited Transthoracic Echocardiography, and Critical Care 
Echocardiography. J Am Soc Echocardiogr. 2020;33(6):676-682. doi:10.1016/j.echo.2020.04.004 
19 Mahmoud-Elsayed HM, Moody WE, Bradlow WM, Khan-Kheil AM, Senior J, Hudsmith LE, Steeds RP. Echocardiographic 
Findings in Patients With COVID-19 Pneumonia. Can J Cardiol. 2020 Aug;36(8):1203-1207. doi: 10.1016/j.cjca.2020.05.030. 
Epub 2020 May 28. PMID: 32474111; PMCID: PMC7255734. 







A prospective service evaluation of PoCUS was completed between the 1st February to 30th 
July 2020.  Service evaluation methodology was employed to define and describe variations 
in approach and evaluate relationships with outcomes during routine clinical practice. All 
adult patients (aged ≥16 years) presenting to participating hospitals with confirmed or 
suspected COVID-19 were eligible for inclusion. All point-of-care LUS and FUSIC Heart 
images obtained for these patients (with confirmed or suspected COVID-19) during their 
acute care admission were eligible for inclusion. The analysis presented is a subset of the 
national evaluation for patients admitted to the ICU of each registered trust.  
 
Demographic and clinical data were recorded using a standard proforma. All point-of-care 
imaging was undertaken by trained practitioners: FAMUS (Focused Acute Medicine 
Ultrasound) or FUSIC Lung and Heart or a higher qualification for transthoracic 
echocardiography. The decision to undertake LUS and the approach to imaging was 
determined by the treating clinician. The ultrasound device used was determined by local 
availability. Serial images on the same patient were identified using a unique study ID 
number.  
 
A data capture tool based on standardised point-of-care imaging protocols was provided.   
LUS findings could be recorded in a maximum of 14 predefined anatomical zones. Clinicians 
recorded whether a 6-point, 12-point or 14-point approach had been undertaken.  A semi-
quantitative severity score was recorded at each anatomical location.  
 
● Score 0: A-lines or < 2 B lines (normal aeration) 
● Score 1: ≥ 2 well-spaced B-lines (moderate loss of aeration) 
● Score 2: Coalescent B lines +/- small consolidations < 1cm (severe loss of aeration) 
● Score 3: Tissue like pattern +/- frank consolidation +/- small consolidations > 1cm 




Summated LUS severity score was approach dependent - in the case of 6-point imaging it 
was between 0-18. Presence of pleural effusion was recorded, and a subjective assessment 
of the pleura for each lung recorded as normal or abnormal.  
Bedside transthoracic echocardiography data collection tool was derived from the FUSIC 
Heart protocol. This involved visual assessment for LV and RV dilatation and function. The 
presence of ventricular dilatation was recorded as a binary variable. Ventricular dysfunction 
was defined as either a dilated or visually impaired left or right ventricle. Advanced, 
quantitative measurements of dilatation and functional impairment were recorded in some 
studies.  
The indication for imaging and any immediate change of management was recorded. 
Patient outcome was recorded at 30-days after the imaging study.   
Statistics  
 
Analysis was performed using the R statistical software. Normally distributed continuous 
variables are described using mean and standard deviation and non-normally distributed 
continuous variables are described using median value and interquartile range. Count data 
is described as proportions with 95% confidence intervals.  
 
Logistic regression was used to explore the relationship between LUS, the PCR result and 30-
day outcomes.  Some patients had repeated imaging obtained. The relationship between 
severity score and mortality was undertaken on the initial scan. Primary analysis was 
restricted to scans performed within 7 days of admission to the intensive care unit. The 
multivariate models included age, sex, interval between ICU admission and study detection 
of SARS-CoV-2 by PCR as fixed effects. Model coefficients are expressed using odds ratios 
where appropriate. The discriminatory performance of the ultrasound severity score to 
predict 30 day mortality was assessed using receiver operating characteristic curves and 










Ethical Approval and Consent to participation 
All participating sites registered the evaluation locally and obtained permission to share 
anonymised data by the relevant Caldicott Guardian. Data were anonymised locally prior to 
transfer to the central database (hosted at the University of Birmingham using Research 
Electronic Data Capture (REDCap) software21) and identified using a unique study 
identification number.  The study had R&I approval locally (East Kent Hospitals University 




                                               
21 PA Harris, R Taylor, BL Minor, V Elliott, M Fernandez, L O’Neal, L McLeod, G Delacqua, F Delacqua, J Kirby, SN Duda, 
REDCap Consortium, The REDCap consortium: Building an international community of software partners, J Biomed Inform. 






ICUs from 12 U.K. hospitals recorded 372 imaging studies in the database between 1st 
February 2020 and 30th July 2020. The median number of studies contributed by individual 
hospitals was 14 (IQR 3 - 40). A total of 372 imaging studies were recorded from 265 ICU 
patients, 72 (27.2%) patients had two studies and 35 (13.5%) patients had more than two 
studies recorded. Paired thoracic imaging and echocardiography were recorded in 333 
(89.5%) studies. Isolated echocardiography in 32 (8.6%) and isolated thoracic imaging was 
undertaken in 7 (1.9%) studies. The median interval between ICU admission and the first 
imaging study was 2 days (IQR 0-8).  
 
The mean patient age was 54 years (12.4) and 187 (70.6%) of patients were male. The SARS-
CoV-2 nasopharyngeal PCR was positive in 219 (82.6%, 95%CI 77.6-86.7) patients at the 
point of the initial imaging study. The SARS-CoV-2 PCR status of 15 (5.7%) patients was 
unknown.  
 
Invasive mechanical ventilation (IMV) was being provided to 320 (86.0%) patients at the 
time of imaging. Non-invasive respiratory support was being provided to 24 (6.5%) patients 
at the time of imaging (Continuous positive airway pressure = 14, high flow nasal support = 
5, and bi-level positive airway pressure support = 5). Death within 30 days of imaging 
occurred in 37 (32.8% 95%CI 27.5 -38.7) patients. The outcome at 30 days was not recorded 
for 15 (5.7%) patients.   
 
Thoracic imaging studies were conducted using a 6-point protocol in 305 (89.7%) patients 
and a 12-point protocol in 35 (10.3%) patients. Missing values in relation to one or more or 
the 6 anatomical thoracic imaging locations occurred in 17 (5.0 %) studies. A single value 








The distribution of 6-point scores stratified by the interval between admission and imaging 
is provided in Figure 1A. The distribution of scores was asymmetric with skew towards 
higher scores. The distribution of scores was broadly similar when stratified by the interval 
between ICU admission and scan. The median score using the 6-point protocol was 11 (8-13 
IQR). Ultrasound severity scores obtained utilising a 12-point protocol were compared to 
the 6-point score derived from the same study..       The 12-point scan did not result in a 
reclassification in the risk quartile in 28 (71%) studies. The 12-point scan resulted in re-
classification into a higher risk quartile in 5 (14.3%) studies and into a lower risk quartile in 2 
(5.7%).   
     Pleural abnormalities were detected in 306 (90.0%) studies       , abnormalities were 
unilateral in 19 (5.6%) studies and bilateral in 287 (84.4%) studies. Unilateral pleural 
effusions were detected in 29 (8.5%) and bilateral pleural effusions were detected in 14 
(4.1%) studies. Of these patients, 5 (35.7%, 95% CI 16.3 -61.2) had simultaneous evidence of 
LV impairment. Preserved A lines in all 6 anatomical zones were observed in 9 (2.6%) studies 
of which 7 (77.8%) were negative for SARS-CoV-2 by PCR.  
 
Indications for scan  
 
The indication and outcome of studies were recorded in the database. The most common 
reason for undertaking imaging was for routine surveillance accounting for 164 studies 
(44.3% 95% CI 39.3-49.4). The indication for imaging and associated distribution of 6-point 
lung ultrasound scores associated with each group is provided in Figure 2 and the outcome 
of scans is provided in Figure 3.  Assessment of extravascular lung water (EVLW) was quoted 
as the indication for imaging in 116 (31.4%, 95%CI 26.8-36.2) studies. Imaging was employed 











There was an     association between the severity of lung involvement (as assessed by 6-
point severity score within 7 days of admission) and 30-day mortality (adjusted OR 1.1 
95%CI 1.0 - 1.2).  
 
      . The discriminatory performance of the ultrasound severity score to predict 30-day 
mortality was poor (AUC 0.58). The observed 30-day mortality associated within quartiles of 
lung severity score stratified by the time interval between ICU admission and the initial 




Echocardiographic studies were recorded from 241 individual patients, of which 174 (72.8%) 
were focused studies and 67 (27.2%) were advanced bedside studies. RV dysfunction was 
identified in 83 (37.7%, 95%CI 31.5-44.3) of the initial studies. RV function was not recorded 
in 6 studies (2.5%). Observed 30-day mortality was significantly higher in patients with RV 
dysfunction compared with patients with normal RV function (49.4% 95%CI 38.9-59.9 vs, 
29.2% 95%CI 22.2-37.3) (     Figure 4B). There was no significant difference in the prevalence 
of RV dysfunction comparing focused echocardiographic studies with advanced bedside 
studies (35.1%, 95%CI 29.4-41.3 vs 36.7%, 95%CI 27.4-47.0). LV dysfunction was identified in 
23 (9.5%, 95%CI 6.4-13.9) of initial studies of which 13 patients died within 30 days (56.5%, 





Paired studies  
 
Comparisons were made between the initial studies and a second study taken at a later 
time point in the 71 cases where serial studies were recorded. The median interval between 
the initial and second study was 4 days (IQR 3-5). There was no statistical difference in mean 
score comparing the initial and later study (mean 9.0 SD 3.6 vs 9.3 SD 3.8, p value = 0.6). The 




in lung severity score was associated with a small      increase in 30-day mortality in a model 
adjusted       for the time interval between imaging studies (adjusted OR 1.2 95%CI 1.0-1.5, p 






This service evaluation is the first national study of its kind at the time of publication. It 
included patients admitted with respiratory failure during the COVID-19 pandemic from 12 
different UK trusts.  Patient demographics from this cohort closely matched ICNARC data22, 
indicating that we studied a generalizable sample. 
   
T     here was a mean time to scan of 2 days from ICU admission, and only 39.5% of patients 
received two or more scans. Serial scan data in our study and other papers have shown 
increased mortality with worsening lung scores23. This suggests that there is currently      
suboptimal provision for serial ICU PoCUS services across the trusts involved and potentially 
nationwide.       
 
However,      i     n our evaluation, combined LUS and FUSIC Heart were performed in 89.5% 
of total patients enrolled. This indicates that, even in severely critically ill COVID-19 patients, 
combined LUS and FUSIC Heart were deliverable alongside the high intensity ICU clinical 
workload across the trusts. Maximum benefit of an ICU POCUS service would more likely be 
achieved with serial scanning of patients with subsequent changes in management rather 
than a focused scan done on ICU admission alone. 
      
 
The correlation between 12-point and 6-point scores supports the role of the 6-point LUS 
protocol in ICU patients24,25. The PosteroLateral Alveolar and/or Pleural Syndrome (PLAPS) is 
                                               
22 Richards-Belle A et al. ‘COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and 
Northern Ireland’. Intensive Care Med. 2020 Nov;46(11):2035-2047. doi: 10.1007/s00134-020-06267-0. Epub 2020 Oct 9. 
PMID: 33034689 
23 Lichter, Y., Topilsky, Y., Taieb, P. et al. Lung ultrasound predicts clinical course and outcomes in COVID-19 patients. 
Intensive Care Med 46, 1873–1883 (2020). https://doi.org/10.1007/s00134-020-06212-1 
 
24 Juvel Mabao Taculod, Kay Choong See, Juliet Sahagun, Yi Lin Tan, Venetia Ong ‘Comparison of 6-Point vs. 12-Point Lung 
Ultrasound for the Diagnosis of Bilateral Lung Infiltrates in ARDS’ Respiratory Care Oct 2018, 63 (Suppl 10) 3015557; 
25 Guang Song, Wei Qiao, Xin Wang, Xiaona Yu. ‘Association of Lung Ultrasound Score with Mortality and Severity of 
COVID-19: A Meta-Analysis and Trial Sequential Analysis’ International Journal of Infectious Diseases, Volume 108, 2021, 




easily achievable and provides good discrimination from the anterior views26,27,28,29.  Clearly 
this is beneficial as movement of COVID-19 patients for posterior views requires additional 
manpower, can be time-consuming and can cause instability.   
 
Typical LUS findings have a good correlation with COVID-19 PCR positivity. This has been 
well studied and published previously30,31,32,33,34,35.  Preserved A-lines in all 6 zones made 
the diagnosis of COVID-19 related respiratory failure extremely unlikely36.  Alveolar-
interstitial syndrome associated with a normal LV function indicates a non-cardiogenic cause 
for respiratory failure. 
 
LUS was able to identify those who had a higher 30-day mortality, particularly if the total 
score was >8 or there was a high score in the PLAPS zones37. The incidence of RV 
                                               
26 H. Xue et al. M-BLUE protocol for coronavirus disease-19 (COVID-19) patients: interobserver variability and correlation 
with disease severity CLinical Radiology 2021Volume 76 Issue 5 p379-383 
27 Mark E. Haaksma, Micah L. A. Heldeweg, Jorge E. Lopez Matta, Jasper M. Smit, Jessica D. van Trigt, Jip S. Nooitgedacht, 
Carlos V. Elzo Kraemer, Armand R.J. Girbes, LeoHeunks, David J. van Westerloo, Pieter R. Tuinman. medRxiv Lung BMJ Yale. 
‘Ultrasound findings in patients with novel SARS-CoV2’ 2020.05.18.20105775; 
https://doi.org/10.1101/2020.05.18.20105775 
28 Soldati, G., Smargiassi, A., Inchingolo, R., Buonsenso, D., Perrone, T., Briganti, D.F., Perlini, S., Torri, E., Mariani, A., 
Mossolani, E.E., Tursi, F., Mento, F. and Demi, L. (2020), Is There a Role for Lung Ultrasound During the COVID-19 
Pandemic?. J Ultrasound Med, 39: 1459-1462. https://doi.org/10.1002/jum.15284 
29 Lerchbaumer, M.H., Lauryn, J.H., Bachmann, U. et al. Point-of-care lung ultrasound in COVID-19 patients: inter- and 
intra-observer agreement in a prospective observational study. Sci Rep 11, 10678 (2021). https://doi.org/10.1038/s41598-
021-90153-2 
30 Zieleskiewicz L, Markarian T, Lopez A, et al. Comparative study of lung ultrasound and chest computed tomography scan 
in the assessment of severity of confirmed COVID-19 pneumonia. Intensive Care Med. 2020;46(9):1707-1713. 
doi:10.1007/s00134-020-06186-0 
31 Ji, L., Cao, C., Gao, Y. et al. Prognostic value of bedside lung ultrasound score in patients with COVID-19. Crit Care 24, 700 
(2020). 
32 Lichter Y, Topilsky Y, Taieb P, Banai A, Hochstadt A, Merdler I, Gal Oz A, Vine J, Goren O, Cohen B, Sapir O, Granot Y, 
Mann T, Friedman S, Angel Y, Adi N, Laufer-Perl M, Ingbir M, Arbel Y, Matot I, Szekely Y. Lung ultrasound predicts clinical 
course and outcomes in COVID-19 patients. Intensive Care Med. 2020 Oct;46(10):1873-1883. doi: 10.1007/s00134-020-
06212-1. Epub 2020 Aug 28. Erratum in: Intensive Care Med. 2020 Sep 25;: PMID: 32860069; PMCID: PMC7454549. 
33 Peris, A., Zagli, G., Barbani, F., Tutino, L., Biondi, S., Di Valvasone, S., Batacchi, S., Bonizzoli, M., Spina, R., Miniati, M., 
Pappagallo, S., Giovannini, V. and Gensini, G.F. (2010), The value of lung ultrasound monitoring in H1N1 acute respiratory 
distress syndrome. Anaesthesia, 65: 294-297. 
34 Kulkarni S, Down B, Jha S. Point-of-care lung ultrasound in intensive care during the COVID-19 pandemic. Clin Radiol. 
2020;75(9):710.e1-710.e4. doi:10.1016/j.crad.2020.05.001 
35 Lieveld AWE, Kok B, Azijli K, Schuit FH, van de Ven PM, de Korte CL, Nijveldt R, van den Heuvel FMA, Teunissen BP, 
Hoefsloot W, Nanayakkara PWB, Bosch FH. Assessing COVID-19 pneumonia-Clinical extension and risk with point-of-care 
ultrasound: A multicenter, prospective, observational study. J Am Coll Emerg Physicians Open. 2021 May 1;2(3):e12429. 
doi: 10.1002/emp2.12429. PMID: 33969350; PMCID: PMC8087918. 
36 Gil-Rodrigo A, Llorens P, Martínez-Buendía C, Luque-Hernández MJ, Espinosa B, Ramos-Rincón JM. Diagnostic yield of 
point-of-care ultrasound imaging of the lung in patients with COVID-19. Emergencias. 2020 Sep;32(5):340-344. English, 
Spanish. PMID: 33006834. 
37 Bonadia N, Carnicelli A, Piano A, Buonsenso D, Gilardi E, Kadhim C, Torelli E, Petrucci M, Di Maurizio L, Biasucci DG, 




dysfunction was more prevalent in our study in those with higher LUS scores (indicating 
more extensive COVID lung involvement)38,39. This study has demonstrated worse outcomes 
in patients with RV dysfunction. This association has been extensively shown in ICU patients 
with RV dysfunction in the context of ARDS and COVID-19 9,40,41,42,43,44 . Lazzeri et al noted 
LUS score and right:left ventricle ratio (representing RV dilatation) were both independent 
predictors of ICU mortality in their observational study of 47 ICU patients17. 
 
Most clinical guidelines used fraction of inspired oxygen concentration (FiO2), oxygen 
saturations and respiratory rate as parameters to identify patients who would benefit from 
critical care referral45. This study suggests that combined LUS score and RV assessment may 
aid in identifying those patients in a worse prognostic group. Patients with high LUS scores 
and RV dysfunction may benefit from earlier ICU admission and closer monitoring. However, 
as this was a service evaluation study, formal research studies will need to be done to assess 
this further.  
 
65% of patients who had POCUS scans had a subsequent change in ICU management (Figure 
3). Management strategies were adapted from literature46 and utilised on a 
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recommendation basis from clinical advisory groups. Many of these guidelines included the 
need for LUS and FUSIC Heart to aid decision making47. These included optimal PEEP 
strategies based on lung compliance and right heart function, decision to prone and 
haemodynamic management strategies aimed at reducing pulmonary hypertension or 
augmenting the systolic RV function.  
 
A systematic review of PoCUS use in patients with undifferentiated shock48 documented 
two ICU based studies where focused echocardiography resulted in a change in patient 
management in 41-51% of patients49,50. These studies focused primarily on shock 
management as an end point. COVID-19 pathophysiology is complex, multi-system, and the 
potential interventions are numerous and interdependent. This may explain why our 
percentage of intervention was higher. However, this study did not measure whether 
interventions led to changes in outcome. There is inherent bias due to this study being 
performed by enthusiastic PoCUS practitioners and so caution must be taken when 
interpreting this observation. 
 
Given the association between LUS score > 8, RV dysfunction and outcome, acquiring this 
information becomes important.  The utility of this information is clear: triaging to a clinical 
area of higher monitoring, instigating pre-emptive management strategies or altering 
existing therapies are all possible.  
 
The combination of these two imaging modalities, LUS and FUSIC Heart, in COVID-19 
patients at ICU admission (or ideally before) provides dynamic clinical information and 
informs the complex interactions between the heart and lungs and the effects, if any, of 
therapeutic intervention. It is therefore crucial to the overall management of this condition.  
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Service evaluation methodology provides insight into how LUS and FUSIC Heart are utilised 
in the delivery of routine care at the expense of a defined study protocol which ensures 
consistency in approach. Based on the observational methodology, the results should be 
interpreted within the constraints and limitations of a service evaluation study.  
 
There was considerable       variation in the time to first imaging study and intervals 
between studies. Including scans performed in the initial 7 days from ICU admission 
introduces a degree of survivor bias. The use of a semi-quantitative score may be an 
oversimplification of a fundamentally subjective assessment. The salient information which 
dictated changes may not have been captured within the ordinal scale used.  
 
This is an evaluation of a service that for most was set up de novo to meet the needs of the 
pandemic. This may explain some of the discrepancies in the results.  It seems less likely that 
a patient admitted to the ICU with severe respiratory failure due to COVID-19 pneumonitis 
had a lung score of zero, which may reflect issues with PoCUS sonographers' training or 
reporting. 
 
In this study, 86% of patients were being mechanically ventilated. The ICNARC data from 1 
September2020 to 30 April 2021* reports 30.6% of patients were mechanically ventilated 
within the first 24 hours. Therefore, caution needs to be taken with regard to interpreting 
the results in this study, as significantly more patients were mechanically ventilated 
compared to current practice. in this study, 6.5% of patients were receiving NIV; LUS and 
FUSIC Heart scanning in these patients are of equal importance and, indeed, may influence 
management changes such as escalation of care and decision to prone. 
 
It is important to note that RV assessment is more challenging than first appreciated.  If the 
left ventricle is hyperdynamic, one may expect the right to be in a similar state.  The fact 
that the right merely appeared to be ‘normally’ functioning may actually represent 




of patients to have an assessment scan. However, the trade-off is that subtle echo signs 
such as apical RV dilatation or early systolic dysfunction may have not been appreciated as 
this would have required an advanced skill set not reliably available on ICUs. 
 
This raises questions around ‘quantity versus quality’ - is it better to provide a screening 
service where most patients have a scan or is it desirable to have a detailed analysis in a 
few, sicker patients?  This question is beyond the scope of this study and requires further 




Our service evaluation suggests that serial, combined LUS and FUSIC Heart can perform an 
important clinical role in identification of COVID-19, risk-stratification of patients, 
monitoring disease progress and guiding interventions on ICU. There was an      association 
between lung ultrasound score, RV dysfunction and mortality in this study. A 12-point 
ultrasound scanning resulted in similar risk predictions to a 6 point scan in the majority of 
case.            Further research studies need to be done to further identify the role of LUS and 
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Figure 1: Lung severity scoring  
 
A: Distribution of 6-point score stratified by the interval between admission and imaging  
B: Distribution of scores stratified by anatomical location  




























Figure 4: 30-day mortality and prevalence of RV dysfunction:  
A:  30-day mortality stratified by ultrasound severity score and interval between admission 
and imaging.  
B: Prevalence of RV dysfunction stratified by ultrasound severity score and interval between 
admission and imaging.  
 
 
Figure 5: Paired imaging studies:  
A: Paired ultrasound severity scores 
B: Initial B line severity score plotted against change in score from the second study. 
 
 
